ES2176475T3 - Composiciones de inhibidor bowman-birk para el tratamiento de enferm edades inflamatorias. - Google Patents

Composiciones de inhibidor bowman-birk para el tratamiento de enferm edades inflamatorias.

Info

Publication number
ES2176475T3
ES2176475T3 ES96926120T ES96926120T ES2176475T3 ES 2176475 T3 ES2176475 T3 ES 2176475T3 ES 96926120 T ES96926120 T ES 96926120T ES 96926120 T ES96926120 T ES 96926120T ES 2176475 T3 ES2176475 T3 ES 2176475T3
Authority
ES
Spain
Prior art keywords
treatment
bowman
birk inhibitor
inhibitor compositions
inflammatory illness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96926120T
Other languages
English (en)
Inventor
Ann R Kennedy
Paul C Billings
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Application granted granted Critical
Publication of ES2176475T3 publication Critical patent/ES2176475T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE DESCRIBE UNA COMPOSICION QUE CONTIENE UN INHIBIDOR BOWMAN BIRK PARA EL TRATAMIENTO DE LA INFLAMACION. TAMBIEN SE DESCRIBEN PROCEDIMIENTOS PARA UTILIZAR ESTA COMPOSICION EN EL TRATAMIENTO DE IBD Y DE LA INFLAMACION HEPATICA.
ES96926120T 1995-07-25 1996-07-25 Composiciones de inhibidor bowman-birk para el tratamiento de enferm edades inflamatorias. Expired - Lifetime ES2176475T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/507,044 US5614198A (en) 1995-07-25 1995-07-25 Bowman-Birk Inhibitor compositions for treatment of inflammatory disease

Publications (1)

Publication Number Publication Date
ES2176475T3 true ES2176475T3 (es) 2002-12-01

Family

ID=24017040

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96926120T Expired - Lifetime ES2176475T3 (es) 1995-07-25 1996-07-25 Composiciones de inhibidor bowman-birk para el tratamiento de enferm edades inflamatorias.

Country Status (13)

Country Link
US (1) US5614198A (es)
EP (1) EP0841933B1 (es)
JP (1) JP4026851B2 (es)
KR (1) KR19990035906A (es)
AT (1) ATE218877T1 (es)
AU (1) AU703476B2 (es)
CA (1) CA2223968A1 (es)
DE (1) DE69621805T2 (es)
DK (1) DK0841933T3 (es)
ES (1) ES2176475T3 (es)
NO (1) NO980289L (es)
PT (1) PT841933E (es)
WO (1) WO1997004792A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040166183A1 (en) * 1998-05-20 2004-08-26 Ruseler-Van Embden Johanna G. H. Methods and means for preventing or treating inflammation or pruritis
EP0958833A1 (en) * 1998-05-20 1999-11-24 Erasmus Universiteit Rotterdam Methods and means for preventing or treating inflammation
DE19906108A1 (de) * 1999-02-13 2000-08-17 Univ Eberhard Karls Schutz von Zellen im Zusammenhang mit einer Behandlung mit chemischen Agenzien
US6391848B1 (en) * 1999-04-30 2002-05-21 The Regents Of The University Of California Soybean protein nutraceuticals
US6767564B2 (en) * 2000-09-02 2004-07-27 The Trustees Of The University Of Pennsylvania Use of bowman birk inhibitor for the treatment of multiple sclerosis and other autoimmune diseases
WO2005074575A2 (en) * 2004-01-30 2005-08-18 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4793996A (en) * 1984-11-14 1988-12-27 Ann R. Kennedy Method of making soybean extract inhibitor
JPS6351335A (ja) * 1986-08-20 1988-03-04 Fuji Oil Co Ltd 肥満細胞脱顆粒抑制剤
US5376373A (en) * 1990-09-06 1994-12-27 Trustees Of The University Of Pennsylvania Method of inhibiting radiation induced weight and hair loss
US5217717A (en) * 1990-09-06 1993-06-08 Central Soya Company, Inc. Method of making soybean Bowman-Birk inhibitor concentrate and use of same as a human cancer preventative and therapy
ATE146970T1 (de) * 1990-10-16 1997-01-15 John Lezdey Behandlung von entzündungen
IT1252865B (it) * 1991-12-31 1995-06-28 Lifegroup Spa N-acilderivati di aminoalcooli attivi come autocoidi locali ed utilizzabili nella terapia dei processi autoimmuni
SE9301911D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptide derivatives

Also Published As

Publication number Publication date
US5614198A (en) 1997-03-25
JP4026851B2 (ja) 2007-12-26
KR19990035906A (ko) 1999-05-25
WO1997004792A1 (en) 1997-02-13
DK0841933T3 (da) 2002-07-15
JPH11510166A (ja) 1999-09-07
AU703476B2 (en) 1999-03-25
PT841933E (pt) 2002-10-31
AU6650196A (en) 1997-02-26
EP0841933B1 (en) 2002-06-12
CA2223968A1 (en) 1997-02-13
ATE218877T1 (de) 2002-06-15
NO980289D0 (no) 1998-01-22
DE69621805T2 (de) 2003-03-20
EP0841933A4 (en) 1998-08-05
DE69621805D1 (de) 2002-07-18
NO980289L (no) 1998-01-22
EP0841933A1 (en) 1998-05-20

Similar Documents

Publication Publication Date Title
TR199902545T2 (xx) Kalp damar hastal�klar�n�n �nlenmesinde siklooksijenaz-2 inhibit�rlerini kullanma y�ntemi
FI20012510L (fi) Fenyyliheterosyklejä syklo-oksigenaasi-2-inhibiittoreina
DK0922697T3 (da) Substituerede pyrazolylbenzensulfonamider og anvendelse deraf som cyclooxygenase II-inhibitorer
BR9809819A (pt) Compostos e métodos para a inibição da expressão de vcam-1
UY24316A1 (es) Composiciones refrescantes
ECSP034441A (es) Tratamiento de depositos de sulfuro de hierro
ES2133807T3 (es) Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas.
BR9403946A (pt) Composição de matéria
FI961886A7 (fi) Ihmisen Kunitz-tyyppiset proteaasi-inhibiittorit
DE69626080D1 (de) Fluorelastomerzusammensetzungen
FI961720L (fi) Uusi koostumus
BG103995A (en) Reverse hydroxamate inhibitors of matrix metalloprreverse hydroxamate inhibitors of matrix metallprooteinases teinases
DE69425786D1 (de) Photoresistzusammensetzung
FI943561L (fi) Uudet ainekoostumukset
ES2170918T3 (es) Inhibidor de proteina quinasa c sustituidos con halo.
DE69417749D1 (de) Nichtklebende zusammensetzung
DK0869965T3 (da) Steroidnitritesterderivater anvendelige som antiinflammatoriske lægemidler
DE69402623D1 (de) Rostschutzzusammensetzung
DE69419101D1 (de) Hochreine thiol-en-zusammensetzung
ES2176475T3 (es) Composiciones de inhibidor bowman-birk para el tratamiento de enferm edades inflamatorias.
FI952459L (fi) Amidoamiinien käyttö oftalmisissa koostumuksissa
BG100248A (bg) Инхибитори на скваленсинтетаза
ID16998A (id) Komposisi batang sabun
ID28711A (id) Komposisi film tepung yang dimodifikasi
FR2772268B1 (fr) Nouvelle composition cosmetique autobronzante et antideshydratante